• A I Villa-Manzano, J I Gamez-Nava, M Salazar-Paramo, I C Valera-Gonzalez, A Garcia-Gonzalez, G Garcia-Gonzalez, J Morales-Romero, A Lopez-Olivo, L M Galvan-Ramirez, R Ruiz-Ruvalcaba, E G Cardona-Muñoz, and L Gonzalez-Lopez.
• Division of Musculoskeletal, Autoinmune and Metabolic Diseases, Clinical Epidemiology Research Unit, Hospital de Especialidades del Centro Medico Nacional de Occidente, IMSS, Guadalajara, Jalisco, México, and Baylor College of Medicine, Houston, TX, USA.
• Rheumatol. Int. 2006 Jun 1;26(8):712-6.

AbstractThe purpose of this study was to assess the association between the serum levels of aminoterminal propeptide of type III procollagen (PIIINP) and carboxyterminal propeptide of type I procollagen (PICP) with disease activity and damage in systemic lupus erythematosus (SLE). Thirty-three patients with SLE were compared with 31 controls. The assessment in SLE included disease activity indices (SLEDAI, MEX-SLEDAI) and damage index (SLICC/ACR). PIIINP and PICP were measured by radioimmunoassay. Compared with controls, mean levels of PIIINP were higher in SLE (2.9+/-1.8 vs. 1.8+/-1.2, P=0.006). PICP was also increased in SLE versus controls (163+/-94 vs. 102+/-62, P=0.007). PIIINP was correlated with SLICC/ACR (r=0.33, P=0.048). No correlation was observed between PICP and PIIINP with other clinical or therapeutic variables. These preliminary data suggests a role of PIIINP as a marker for chronic damage. Follow-up studies are required to evaluate its utility in predicting future damage.

20 keywords...

hide…